US Drug Recall Register

FDA Drug Recalls

1,523 recalls · Class III, newest first

Class III · Low risk Terminated

Mycophenolate Mofetil

Reason cGMP deviation; manufacturer is Not Registered with the Food and Drug Administration

Attix Pharmaceuticals Inc D-1047-2016
Class III · Low risk Terminated

VP-CH-PNV Prenatal/Postnatal capsules

Reason Defective delivery system: Softgel capsules are leaking.

Virtus Pharmaceuticals, Llc NDC 69543-224-30 D-1048-2016
Class III · Low risk Terminated

Hyoscyamine Sulfate Sublingual Tablets

Reason Chemical Contamination: Bottles may contain broken dessicants

Virtus Pharmaceuticals, Llc NDC 76439-0309-10 D-1044-2016
Class III · Low risk Terminated

Benzphetamine Hydrochloride Tablets

Reason Discoloration: presence of scuffing marks on tablets.

KVK-Tech, Inc. NDC 10702-0040-03 D-1057-2016
Class III · Low risk Terminated

Dicloxacillin Sodium Capsules USP

Reason Failed Impurities/Degradation Specifications:Out of specification result for a known impurity obtained during testing.

Sandoz, Inc NDC 0781-2258-01 D-1046-2016
Class III · Low risk Terminated

Dicloxacillin Sodium Capsules

Reason Failed Impurities/Degradation Specifications:Out of specification result for a known impurity obtained during testing.

Sandoz, Inc NDC 0781-2248-01 D-1045-2016
Class III · Low risk Terminated

Hectorol

Reason Labeling: Wrong barcode. An incorrect bar code was noted on the vial label of Hectorol 2 mcg/1mL vial.

Genzyme Corporation / Genzyme Biosurgery NDC 58468-0126-1 D-1029-2016
Class III · Low risk Terminated

CVS pharmacy Original Strength Acid Controller tablets

Reason Failed impurities/degradation specification: An out of specification results has been determined for an individual related substance during stability testing at the 18th month interval for the Famotidine 10 mg Tablet, USP.

Dr. Reddy's Laboratories, Inc. D-1058-2016
Class III · Low risk Terminated

Acetaminophen & Codeine Phosphate Tablets

Reason Labeling: Not elsewhere classified - count on the label was incorrect.

A-S Medication Solutions LLC. NDC 54569-8305-0 D-0839-2016
Class III · Low risk Terminated

SKY Aspirin Chewable Tablets

Reason Labeling: Label mix-up -outer carton incorrectly labeled as aspirin chewable tablets.

Mckesson Packaging Services NDC 63739-434-01 D-0834-2016
Class III · Low risk Terminated

BuPROPion Hydrochloride Extended-release Tablets

Reason Failed Impurities/Degradation Specifications: high out of specification results for one of the known degradation products, m-chlorobenzoic acid.

Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-317-60 D-0671-2017
Class III · Low risk Terminated

BuPROPion Hydrochloride Extended-release Tablets

Reason Failed Impurities/Degradation Specifications: high out of specification results for one of the known degradation products, m-chlorobenzoic acid.

Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-316-60 D-0670-2017
Class III · Low risk Terminated

BuPROPion Hydrochloride Extended-release Tablets

Reason Failed Impurities/Degradation Specifications: high out of specification results for one of the known degradation products, m-chlorobenzoic acid.

Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-315-60 D-0669-2017
Class III · Low risk Terminated

Haloperidol Decanoate Injection

Reason Failed Impurities/Degradation Specifications: Firm is recalling product due to an impurity out-of-specification result.

Fresenius Kabi USA, LLC NDC 63323-469-01 D-0818-2016
Class III · Low risk Terminated

Lisinopril Tablets USP

Reason CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose intermediates failed specifications.

Lupin Pharmaceuticals Inc. NDC 68180-517-03 D-1503-2016
Class III · Low risk Terminated

Lisinopril Tablets USP

Reason CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose intermediates failed specifications.

Lupin Pharmaceuticals Inc. NDC 68180-516-02 D-1502-2016
Class III · Low risk Terminated

Lisinopril & Hydrochlorothiazide Tables

Reason CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose intermediates failed specifications.

Lupin Pharmaceuticals Inc. NDC 68180-519-01 D-1052-2016